Stock DICOT DICOT AB
Add to a list
To use this feature you must be a member
Log inSign up

Dicot AB

Equities

DICOT

SE0011178458

End-of-day quote NORDIC GROWTH MARKET
Other stock markets
 06:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
0.2125 SEK -2.97% Intraday chart for Dicot AB -21.00% -33.18%
Mar. 11 Dicot AB Announces Recruitment Completed in Dicot's Phase 1 Trial CI
Feb. 26 Dicot AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Dicot AB

Dicot AB Announces Recruitment Completed in Dicot's Phase 1 Trial CI
Dicot AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Dicot AB Presents Positive Results from the First Part of its Phase 1 Clinical Study CI
Dicot Files New Manufacturing Technology Patent in Sweden; Stock Rises MT
Dicot Applies for Patent Covering New Manufacturing Technology CI
Dicot AB Announces Partial Results from Phase 1 Trial to Be Presented Early Next Year CI
Dicot AB Initiates Repeat Dosing in its Clinical Study CI
Dicot AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Dicot Sets TO5 Warrant Exercise Price in Rights Issue MT
Dicot AB Initiates Repeated Dosing in Phase I Study CI
The Second Part of Dicot's Phase 1 Study Starts on October 20, 2023 CI
Swedish Pharma Company Dicot Files Application under Patent Cooperation Treaty MT
Dicot AB Applies for International Patent Protection CI
Dicot AB Announces First Participants Dosed in Phase 1 Trial CI
Dicot AB Applies for US Patent CI
Dicot AB Announces Clinical Phase 1 Study Starts CI
Dicot AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Dicot AB Receives Approval to Start Phase 1 Clinical Trial CI
Certain Common Shares of Dicot AB are subject to a Lock-Up Agreement Ending on 26-JUL-2023. CI
Dicot AB Submits Application to Start Clinical Phase 1 Trial CI
Dicot AB Announces Success in Collaboration with Uppsala University and W. Szafer Institute of Botany CI
Dicot to Seek Initiation of a Phase I Clinical Trial for the Drug Candidate Lib-01 CI
Dicot AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Dicot's Study Drug Arrives in Sweden CI
Dicot AB Appoints Mats Silvander as New chief technical officer CI

Chart Dicot AB

Chart Dicot AB
More charts

Company Profile

More about the company

Income Statement Evolution

More financial data
  1. Stock Market
  2. Equities
  3. DICOT Stock
  4. News Dicot AB
  5. Dicot : Makes Partially Secured $3 Million Rights Issue